**Maternal and neonatal seroprevalence of Hepatitis B surface antigen (HBsAg) in Tripoli, Libya**

Hamida El-Magrahe1, Abdul Rahaman Furarah2, Kheiria El-Figih2, Sued El-Urshiffany3, Khalifa Sifaw Ghenghesh2

1Faculty of Sciences, Al-Fateh University, Tripoli, Libya
2Faculty of Medicine, Al-Fateh University for Medical Sciences, Tripoli, Libya
3Tripoli Medical Center, Tripoli, Libya

**Abstract**

Background: Pregnant women with Hepatitis B virus HBV represent a major reservoir of the virus in the community. Data regarding the prevalence of HBV in pregnant women and maternal transmission of the virus in Libya are lacking.

Methodology: Hepatitis blood samples from 1,500 pregnant women and 1,500 cord blood samples of their neonates delivered at Tripoli Medical Center, Tripoli, were tested for HBsAg by ELISA technique. HBsAg-positive samples were also tested for HBeAg.

Results: HBsAg was detected in 1.5% (23/1,500) pregnant women and in 0.9% (14/1,500) neonates. Although HBsAg was detected at higher rate in pregnant women aged > 25 years [1.8% (22/1,235)] than in pregnant women aged < 25 years [0.4% (1/265)], the difference was not statistically significant (P > 0.05). All HBsAg-positive neonates were born to HBsAg-positive mothers with a rate of maternal transmission at 60.9% (14/23). HBeAg was detected in 21.7% (5/23) and in 7.1% (1/14) of HBsAg-positive pregnant women and neonates, respectively.

Conclusions: Because of the high risk of developing chronic HBV infection at birth among infants born to HBsAg-positive mothers, administration of HBIG in combination with hepatitis B vaccine as post-exposure prophylaxis for such infants is of paramount importance. In addition, universal HBsAg screening of all pregnant women will greatly assist in reducing the maternal transmission of HBV in the country.

**Key words:** hepatitis B; seroprevalence; maternal transmission; Tripoli, Libya


(Received 23 October 2009 – Accepted 23 October 2009)

Copyright © 2010 El-Magrahe et al. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Materials and Methods**

From April 2001 to March 2002 blood samples from 1,500 pregnant women [aged < 21 to > 35 years (mean = 28 years)] and 1,500 cord blood samples of their neonates delivered at Tripoli Medical Center, Tripoli, Libya, were tested for HBsAg using ELISA techniques according to the manufacture’s recommendations (Organon Teknika, WB Boxtel, The Netherlands). Blood samples positive for HBsAg were also tested for HBeAg. Informal consent was obtained from all participants in the study before blood samples were collected. None of the mothers reported being vaccinated against HBV, or taking intravenous drugs. For statistical analysis, the Epi-2000 software [Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA] was employed. P-values were calculated using Chi-squares test and a P-value < 0.05 was considered statistically significant.

**Introduction**

Hepatitis B virus (HBV), a DNA virus transmitted percutaneously, sexually and perinatally, affects 350-400 million individuals worldwide (1). HBV causes acute and chronic infections of the liver. Chronic HBV infection at birth occurs in approximately 90% of infants born to HBV surface antigen (HBsAg)- and hepatitis B e-antigen (HBeAg)-positive mothers (2,3). In addition, maternal transmission of HBV predisposes infected newborns to liver cirrhosis and hepatocellular carcinoma in young adulthood (4).

Data regarding the prevalence of HBV in pregnant women and maternal transmission of the virus in Libya are lacking. The aim of this study is to determine the seroprevalence of HBV infection in pregnant women in Tripoli, Libya, and to estimate the risk of perinatal transmission in women positive for HBsAg.
Results

HBsAg was detected in 23 (1.5%) pregnant women and in 14 (0.9%) neonates. Although HBsAg was detected at higher rate in pregnant women aged > 25 years [1.8% (22/1,235)] than in pregnant women aged < 25 years [0.4% (1/265)], the difference was not statistically significant (P > 0.05). All HBsAg-positive neonates were born to HBsAg-positive mothers with a rate of maternal transmission at 60.9% (14/23). HBeAg was detected in 21.7% (5/23) and 7.1 (1/14) of HBsAg-positive pregnant women and HBsAg-positive neonates, respectively.

Discussion

Hepatitis B virus and hepatitis C virus are responsible for the majority of chronic liver disease cases and leading causes of hepatocellular carcinoma in Libya (5). Studies conducted during the nineties of last century have reported HBsAg seroprevalence rates between 4.3-4.6% among the Libyan population (6,7). Recently, a general population-based HBV seroprevalence nationwide survey performed in Libya (65,300 participants) reported a seroprevalence rate of 2.2% for HBsAg (8). We detected HBsAg in 1.5% of the pregnant women examined, which is lower than the rate reported in the general Libyan population. This result could be due to the fact that HBV infection in Libya is related, among other factors, to the male gender (5).

Also, the prevalence of seropositive HBsAg among pregnant women in the present study is low in comparison with the prevalence rates reported from the North Africa and the Middle East regions. HBsAg seroprevalence rates in pregnant women of 4%, 5.6% and 15.3% have been reported from the neighboring countries Tunisia (9), Sudan (10) and Egypt (11), respectively. Studies from the Middle East reported rates of 4.3% from Jordan (12) and 2.4% from Saudi Arabia (13). High prevalence rates of HBsAg were also reported from Ghana (10.5%) (14), Nigeria (10.3%) (15) and Yemen (13.2%) (16). Geographical differences may explain the variation in seroprevalence rates of HBsAg among pregnant women from different countries. Studies have shown that variation may even exist among regions of the same country (13,17).

Several studies reported that HBV infection in pregnant women increased with age (16,17). In the present investigation no significant difference in the prevalence of HBsAg in different age groups was observed. Similar results were reported by other investigators (10,14,17).

Worldwide perinatal transmission of HBV is an important route of infection. Studies have shown vertical transmission of HBsAg between 10 and 85% (18). Onakewhor et al. (19) examined 320 mother and neonatal cord blood pairs, and reported neonatal seroprevalence of HBsAg of 0.96% and vertical transmission rate of 42.9%. We examined 1,500 mother and neonatal cord blood pairs and found a closely similar seroprevalence rate of HBsAg among the neonates examined (0.9%); however, the vertical transmission rate was higher in the present study (60.9%). Badawy and El-Salahy (11) reported a rate of materno-fetal transmission in 51.8% of HBsAg-positive women in Egypt. Lower perinatal transmission rates of HBV have been reported from Bangladesh (12.8%) (20) and India (17%) (21). Reported variable vertical transmission rates from HBsAg-mothers to their infants depend on several factors, including viral load, HBV variants and sensitivity and accuracy of diagnostic tests (22).

HBeAg was detected in 21.7% (5/23) of HBsAg-positive mothers. This marker correlates with level of infectivity; an HBeAg-positive pregnant mother is most likely to transmit the virus to the fetus. In this study, HBeAg was detected only in one (7.1%) HBsAg-positive neonate. Nas et al. (23) detected HBeAg in 7.5% of HBsAg-positive pregnant women in Ankara, Turkey. On the other hand, Al-Shamahy (16) reported a rate of 60% for HBeAg among HBsAg-positive mothers in Sana’a, Yemen.

In Libya, HBV vaccine has been provided since 1993 free of charge to all newborns. In 2000 the Secretary of Health recommended anti-natal screening and in 2005 a mass HBV vaccination campaign was carried out targeting adolescents born in 1990 to 1992 (5). Such actions doubtlessly will contribute to the reduction of HBV in the future in Libya. However, chronic HBV infection remains a major health care problem in Libya (5). This study showed a high rate (> 60%) of maternal transmission of HBV among HBsAg-positive mothers in Tripoli. Because of the high risk of developing chronic HBV infection at birth among infants born to HBsAg-positive mothers, the administration of HBIG in combination with hepatitis B vaccine as post-exposure prophylaxis for such infants is of paramount importance. In addition, universal HBsAg screening of all pregnant women will greatly assist in reducing the maternal transmission of HBV in the country.
References


Corresponding author
Professor Khalifa Sifaw Ghenghesh, MSc, PhD, DipBact
Department of Microbiology and Immunology
Faculty of Medicine
Al-Fateh University for Medical Sciences
PO Box 80013
Tripoli-Libya
Email: ghenghesh_micro@yahoo.com

Conflict of interest: No conflict of interests is declared.